ArticleOncotarget2016
High expression of microRNA-454 is associated with poor prognosis in triple-negative breast cancer.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- MicroRNAs in the prognosis of triple-negative breast cancer: A systematic review and meta-analysis.Medicine · 2017Pooled it
- Article
- A dynamic microRNA profile that tracks a chemotherapy resistance phenotype in osteosarcoma. Implications for novel therapeutics.medRxiv : the preprint server for health sciences · 2024Article
- ER Negative Breast Cancer and miRNA: There Is More to Decipher Than What the Pathologist Can See!Biomedicines · 2023Review
- Review
- The Role of miRNAs in the Prognosis of Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis.Diagnostics (Basel, Switzerland) · 2022Review
- Multi-Level Analysis of Adipose Tissue Reveals the Relevance of Perivascular Subpopulations and an Increased Endothelial Permeability in Early-Stage Lipedema.Biomedicines · 2022Article
- Recent advances of transcriptomics and proteomics in triple-negative breast cancer prognosis assessment.Journal of cellular and molecular medicine · 2022Review
- Alteration of miR-362-5p and miR-454-3p expression elicits diverse responses in breast cancer cell lines.Molecular biology reports · 2022Article
- Long non-coding RNA SNHG1 stimulates ovarian cancer progression by modulating expression of miR-454 and ZEB1.Molecular oncology · 2021Article
- Rank-preserving biclustering algorithm: a case study on miRNA breast cancer.Medical & biological engineering & computing · 2021Article
- Cytochrome b561 Serves as a Potential Prognostic Biomarker and Target for Breast Cancer.International journal of general medicine · 2021Article
- MicroRNA-133b expression inversely correlates with MET and can serve as an optimum predictive biomarker for patients of colorectal cancer.Translational cancer research · 2021Article
- High Expression of microRNA-223 Indicates a Good Prognosis in Triple-Negative Breast Cancer.Frontiers in oncology · 2021Article
- Secreted breast tumor interstitial fluid microRNAs and their target genes are associated with triple-negative breast cancer, tumor grade, and immune infiltration.Breast cancer research : BCR · 2020Article
- miR-454 suppresses the proliferation and invasion of ovarian cancer by targeting E2F6.Cancer cell international · 2020Article
- LncRNA XIST interacts with miR-454 to inhibit cells proliferation, epithelial mesenchymal transition and induces apoptosis in triple-negative breast cancer.Journal of biosciences · 2020Article
- Construction of a Potential Breast Cancer-Related miRNA-mRNA Regulatory Network.BioMed research international · 2020Article
- Prognostic role of microRNAs in breast cancer: A systematic review.Oncotarget · 2019Article
- VGLL4 interacts with STAT3 to function as a tumor suppressor in triple-negative breast cancer.Experimental & molecular medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNA-454 (miR-454) has been reported to play an oncogenic or tumor suppressor role in most cancers. However, the clinical relevance of miR-454 in breast cancer remains unclear. We examined the expression of miR-454 in a tissue microarray containing 534 breast cancer specimens from female patients at Fudan University Shanghai Cancer Center using in situ hybridization (ISH). Of these, 250 patients formed the training set and the other 284 were the validation set. The relationship between miR-454 and clinical outcome was analyzed by the Kaplan-Meier method. High expression of miR-454 indicated worse disease-free survival (DFS) in both cohorts (P = 0.006 for training set; P = 0.010 for validation set). Furthermore, in the triple-negative breast cancer (TNBC) subtype, miR-454 was positively correlated with worse clinical outcome (P = 0.013 for training set, P = 0.014 for validation set). In addition, patients in the low miR-454 expression cohort had better response to anthracycline compared to non-anthracycline chemotherapy (P = 0.056), but this difference was not observed in the high miR-454 expression cohort. Our findings indicated that miR-454 is a potential predictor of prognosis and chemotherapy response in TNBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.